Literature DB >> 2532082

Steroid responses to ACTH in women with polycystic ovaries.

W M Hague1, J W Honour, J Adams, P Vecsei, H S Jacobs.   

Abstract

Sixty-three women with ultrasonically detected polycystic ovaries (PCO) were investigated for a disorder of adrenal steroid biosynthesis. Serum was obtained before, and at 30 and 60 min after, the administration of 250 micrograms tetracosactrin, and assayed for 17 alpha-OH-progesterone, 21-deoxycortisol, 17 alpha-OH-pregnenolone and dehydroepiandrosterone by radioimmunoassay following paper chromatography. Results were compared with those in 11 women with normal ovaries, seven adult females with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21OHD), and 15 women heterozygous for this defect. Although the basal-peak steroid concentration differences were significantly greater when ACTH tests were conducted between 1400 and 1700 h than between 0900 and 1000 h, absolute peak steroid concentrations were not different at either time of day. Four of 63 (6.4%) women with PCO had responses to ACTH characteristic of non-classical (late onset) 21OHD CAH, and about half the remainder had responses characteristic of 21OHD heterozygotes. There was no clear cut evidence for a deficiency in 3 beta-hydroxysteroid dehydrogenase activity in women with PCO.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2532082     DOI: 10.1111/j.1365-2265.1989.tb00433.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  2 in total

1.  Hirsutism in the United Arab Emirates: a hospital study.

Authors:  O B Gatee; H M Al Attia; I A Salama
Journal:  Postgrad Med J       Date:  1996-03       Impact factor: 2.401

2.  Adrenocortical steroid response to ACTH in different phenotypes of non-obese polycystic ovary syndrome.

Authors:  Nese Cinar; Ayla Harmanci; Duygu Yazgan Aksoy; Kadriye Aydin; Bulent Okan Yildiz
Journal:  J Ovarian Res       Date:  2012-12-07       Impact factor: 4.234

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.